User profiles for JAMES L. ABBRUZZESE
James L. AbbruzzeseProfessor of Medicine, Duke University Verified email at duke.edu Cited by 75302 |
Pancreatic cancer
D Li, K Xie, R Wolff, JL Abbruzzese - The Lancet, 2004 - thelancet.com
Pancreatic cancer remains a major unsolved health problem, with conventional cancer
treatments having little impact on disease course. Almost all patients who have pancreatic cancer …
treatments having little impact on disease course. Almost all patients who have pancreatic cancer …
Phase II trial of curcumin in patients with advanced pancreatic cancer
…, RA Wolff, AB Kunnumakkara, JL Abbruzzese… - Clinical cancer …, 2008 - AACR
Purpose: Pancreatic cancer is almost always lethal, and the only US Food and Drug
Administration–approved therapies for it, gemcitabine and erlotinib, produce objective responses in …
Administration–approved therapies for it, gemcitabine and erlotinib, produce objective responses in …
[PDF][PDF] Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
…, HQ Xiong, E Rowinsky, JL Abbruzzese… - Journal of Clinical …, 2006 - biostat.wisc.edu
… Moore MJ, Hirte HW, Siu L, et al: Phase I study to determine the safety and pharmacokinetics
of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days …
of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days …
Metastatic patterns in adenocarcinoma
…, W Wei, MN Raber, R Lenzi, JL Abbruzzese - Cancer, 2006 - Wiley Online Library
BACKGROUND Unique metastatic patterns cited in the literature often arise from anecdotal
clinical observations and autopsy reports. The authors analyzed clinical data from a large …
clinical observations and autopsy reports. The authors analyzed clinical data from a large …
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer
…, KF Fournier, H Wang, L Marquis, JL Abbruzzese… - Cancer research, 2009 - AACR
A better understanding of drug resistance mechanisms is required to improve outcomes in
patients with pancreatic cancer. Here, we characterized patterns of sensitivity and resistance …
patients with pancreatic cancer. Here, we characterized patterns of sensitivity and resistance …
The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells
W Wang, JL Abbruzzese, DB Evans, L Larry… - Clinical Cancer …, 1999 - AACR
Pancreatic adenocarcinoma is a leading cause of adult cancer mortality in the United States.
Recent studies have revealed that point mutation of the K-ras oncogene is a common event …
Recent studies have revealed that point mutation of the K-ras oncogene is a common event …
Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus
…, LY Hwang, CJ Hatten, M Swaim, D Li, JL Abbruzzese… - Hepatology, 2002 - Elsevier
Risk factors associated with hepatocellular carcinoma (HCC) are well documented, but the
synergisms between these risk factors are not well examined. We conducted a hospital-based…
synergisms between these risk factors are not well examined. We conducted a hospital-based…
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy
GR Varadhachary, EP Tamm, JL Abbruzzese… - Annals of surgical …, 2006 - Springer
With recent advances in pancreatic imaging and surgical techniques, a distinct subset of
pancreatic tumors is emerging that blurs the distinction between resectable and locally …
pancreatic tumors is emerging that blurs the distinction between resectable and locally …
[HTML][HTML] Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group …
…, CM Fenoglio-Preiser, JL Abbruzzese… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Patients with advanced pancreas cancer present with disease that is poorly
responsive to conventional therapies. Preclinical and early clinical evidence has supported …
responsive to conventional therapies. Preclinical and early clinical evidence has supported …
[PDF][PDF] Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head
…, EA Lano, L Ho, R Lenzi, JL Abbruzzese… - Journal of clinical …, 2008 - researchgate.net
… Pisters PWT, Abbruzzese JL, Janjan NA, et al: Rapid-fractionation preoperative
chemoradiation, PD, and intraoperative radiation therapy for resectable pancreatic …
chemoradiation, PD, and intraoperative radiation therapy for resectable pancreatic …